[go: up one dir, main page]

MX2011008944A - Tratamiento de trastornos relacionados con la discinesia. - Google Patents

Tratamiento de trastornos relacionados con la discinesia.

Info

Publication number
MX2011008944A
MX2011008944A MX2011008944A MX2011008944A MX2011008944A MX 2011008944 A MX2011008944 A MX 2011008944A MX 2011008944 A MX2011008944 A MX 2011008944A MX 2011008944 A MX2011008944 A MX 2011008944A MX 2011008944 A MX2011008944 A MX 2011008944A
Authority
MX
Mexico
Prior art keywords
treatment
related disorders
methods
treating
dyskinesia
Prior art date
Application number
MX2011008944A
Other languages
English (en)
Other versions
MX340138B (es
Inventor
Morten Joergensen
Benny Bang-Andersen
Niels Moerk
Jennifer Larsen
Haakan Wikstroem
Lars Torup
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42060693&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011008944(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MX2011008944A publication Critical patent/MX2011008944A/es
Publication of MX340138B publication Critical patent/MX340138B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En la presente se describen métodos de tratamiento de la enfermedad de Parkinson manteniendo un perfil de inducción a discinesia bajo y a métodos de revertir discinesias que comprende la administración de una cantidad terapéuticamente efectiva de un compuesto de la invención. La presente invención además se relaciona con los usos y composiciones farmacéuticas de dichos compuestos en la fabricación de medicamentos para tratar la misma.
MX2011008944A 2009-02-27 2010-02-26 Tratamiento de trastornos relacionados con la discinesia. MX340138B (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US15594309P 2009-02-27 2009-02-27
US15596609P 2009-02-27 2009-02-27
US15595309P 2009-02-27 2009-02-27
DKPA200900281 2009-02-27
DKPA200900280 2009-02-27
DKPA200900273 2009-02-27
PCT/DK2010/050051 WO2010097092A1 (en) 2009-02-27 2010-02-26 Treatment of dyskinesia related disorders

Publications (2)

Publication Number Publication Date
MX2011008944A true MX2011008944A (es) 2011-09-15
MX340138B MX340138B (es) 2016-06-28

Family

ID=42060693

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008944A MX340138B (es) 2009-02-27 2010-02-26 Tratamiento de trastornos relacionados con la discinesia.

Country Status (19)

Country Link
US (1) US20120108624A1 (es)
EP (2) EP2400967B1 (es)
JP (1) JP5738775B2 (es)
KR (1) KR101700978B1 (es)
CN (1) CN102333531B (es)
AR (1) AR075625A1 (es)
AU (1) AU2010217059B2 (es)
BR (1) BRPI1007017A2 (es)
CA (1) CA2751322C (es)
CL (1) CL2011002102A1 (es)
CO (1) CO6410297A2 (es)
EA (1) EA023778B1 (es)
IL (1) IL213502A (es)
MX (1) MX340138B (es)
NZ (1) NZ594264A (es)
SG (1) SG174163A1 (es)
TW (1) TW201036949A (es)
WO (1) WO2010097092A1 (es)
ZA (1) ZA201106294B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019101917A1 (en) * 2017-11-24 2019-05-31 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
WO2020070099A1 (en) 2018-10-02 2020-04-09 H. Lundbeck A/S Administration of catecholamine prodrugs in combination with a 5-ht2b antagonist
US12319686B2 (en) 2019-01-17 2025-06-03 Hoffmann-La Roche Inc. Process for the preparation of tetrahydropyridopyrimidines
US11104697B2 (en) * 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) * 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
CN113727979B (zh) 2019-05-21 2024-09-20 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
JP7514859B2 (ja) * 2019-05-21 2024-07-11 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
CN119707810A (zh) * 2019-05-21 2025-03-28 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
WO2020234277A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
US20240025857A1 (en) 2020-11-17 2024-01-25 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
WO2023208867A1 (en) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab NOVEL 1,2,3,4,4a,5,8,9,10,10a-DECAHYDROBENZO[G]QUINOLIN-6(7H)-ONE COMPOUNDS AND USES THEREOF
US20250282733A1 (en) 2022-04-25 2025-09-11 Integrative Research Laboratories Sweden Ab Novel 1,2,3,4,4a,5,6,7,8,9,10,10a-dodecahydrobenzo[g]quinolin-6-ol compounds and uses thereof
US20250282732A1 (en) 2022-04-25 2025-09-11 Integrative Research Laboratories Sweden Ab NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[G]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF
WO2025078571A1 (en) 2023-10-12 2025-04-17 Integrative Research Laboratories Sweden Ab NOVEL CARBONATES AND CARBAMATES OF 1,2,3,4,4a,5,6,7,8,9,10,10a- DODECAHYDROBENZO[g]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF
WO2025078574A1 (en) 2023-10-12 2025-04-17 Integrative Research Laboratories Sweden Ab NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[g]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0001438D0 (sv) * 2000-04-18 2000-04-18 Axon Chemicals Bv New chemical compounds and their use in therapy
TWI404702B (zh) 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥
US20090124651A1 (en) * 2007-08-31 2009-05-14 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof

Also Published As

Publication number Publication date
TW201036949A (en) 2010-10-16
AU2010217059A1 (en) 2011-08-11
CA2751322C (en) 2017-10-31
JP2012519157A (ja) 2012-08-23
CO6410297A2 (es) 2012-03-30
NZ594264A (en) 2013-11-29
EA201171088A1 (ru) 2012-02-28
HK1166472A1 (en) 2012-11-02
EP2400967A1 (en) 2012-01-04
KR20110132340A (ko) 2011-12-07
EA023778B1 (ru) 2016-07-29
US20120108624A1 (en) 2012-05-03
AR075625A1 (es) 2011-04-20
CN102333531A (zh) 2012-01-25
BRPI1007017A2 (pt) 2016-03-29
JP5738775B2 (ja) 2015-06-24
IL213502A (en) 2017-02-28
ZA201106294B (en) 2012-10-31
WO2010097092A1 (en) 2010-09-02
CN102333531B (zh) 2013-11-06
CL2011002102A1 (es) 2012-07-20
MX340138B (es) 2016-06-28
SG174163A1 (en) 2011-10-28
EP2400967B1 (en) 2019-08-14
CA2751322A1 (en) 2010-09-02
KR101700978B1 (ko) 2017-01-31
IL213502A0 (en) 2011-07-31
AU2010217059B2 (en) 2012-08-30
EP3653210A1 (en) 2020-05-20

Similar Documents

Publication Publication Date Title
MX2011008944A (es) Tratamiento de trastornos relacionados con la discinesia.
MX2024000208A (es) Restos de administracion terapeutica novedosos y usos de estos.
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
HK1206297A1 (en) Pharmaceutical compositions for combination therapy
IN2012MN02591A (es)
HK1201065A1 (en) Novel quinoxaline inhibitors of pi3k
MY183582A (en) Deuterated cftr potentiators
GB201118656D0 (en) New compounds
MX2009010407A (es) Derivados fluorados de deferiprona.
UA111588C2 (uk) Композиція інгібітора jak для місцевого застосування
MX349159B (es) Derivados deuterados de ivacaftor.
WO2008086014A3 (en) Bis-aryl amide derivatives useful for the treatment of cancer
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
MY153062A (en) Methods of treating gastrointestinal disorders independent of the intake of food
WO2010071826A3 (en) Methods for treating osteoclast-related disease, compounds and compositions thereof
UA101393C2 (ru) КОМПОЗИЦИИ И ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ ТРИАЗОЛА ДЛЯ ЛЕЧЕНИЯ β-АМИЛОИДОЗОВ И СИНУКЛЕИНОПАТИЙ
WO2012050831A3 (en) Combination treatment for dermatological conditions
WO2013085849A3 (en) Sulfate esters of noribogaine
WO2013040227A3 (en) Therapeutic compounds
MX2010003269A (es) Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
IN2015MN00131A (es)
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
PL2244703T3 (pl) Lekarstwo, jego wytwarzanie i zastosowanie w leczeniu bolesnych neuropatii
EA201290856A1 (ru) Стабилизированная фармацевтическая композиция
MX336278B (es) Composiciones y metodos para la prevencion y el tratamiento de heridas.

Legal Events

Date Code Title Description
FG Grant or registration